Track H. Lundbeck A/S — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

H. Lundbeck A/S LUN.CO Open H. Lundbeck A/S in new tab

172.70 DKK
Yield
2.64%
Safety Score
92
Loading chart...
Dividend
Dividend Yield2.64%
Annual dividends1.15 DKK
Ex-Div. DateMarch 24, 2022
Payout29.54%

DCF Valuation

Tweak assumptions to recompute fair value for H. Lundbeck A/S (LUN.CO)
Currency: DKK
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

H. Lundbeck A/S Logo H. Lundbeck A/S Analysis (LUN.CO)

Denmark Health Care Official Website Stock

Is H. Lundbeck A/S a good investment? H. Lundbeck A/S (LUN.CO) is currently trading at 172.70 DKK.

For income investors, H. Lundbeck A/S pays a dividend yield of 2.64%. With a payout ratio of 30%, the dividend appears sustainable.

Investor FAQ

Does H. Lundbeck A/S pay a dividend?

Yes, it pays an annual dividend of 1.15 DKK (2.64% yield).

What asset class is H. Lundbeck A/S?

H. Lundbeck A/S is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Exchange Ticker
CPH (Denmark) LUN.CO
Dividend Yield

2.64%

Annual Dividends

1.15 DKK

Next ex. div date

March 24, 2022

Payout Ratio

29.54%

Historical Dividends
Year Total Dividends
2022 2.00 DKK
2021 2.50 DKK
2020 4.10 DKK
2019 12.00 DKK
2018 8.00 DKK
2017 2.45 DKK
2014 2.77 DKK
2013 2.00 DKK
2012 6.98 DKK
2011 3.77 DKK
2010 3.07 DKK
2009 2.30 DKK
2008 2.56 DKK
2007 1.57 DKK
2006 2.10 DKK
2005 2.21 DKK
2004 1.77 DKK
2002 1.14 DKK

Yearly aggregated dividends

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion